Search Results - "Karol, Seth"

Pediatric acute myeloid leukemia - novel approaches by Karol, Seth E, Gueguen, Gwenaelle

“…Despite higher remission and survival rates than observed in adults, children with acute myeloid leukemia (AML) still suffer unacceptably high rates of…”
Get full text

Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response by Lee, Shawn H. R., Yang, Wenjian, Gocho, Yoshihiro, John, August, Rowland, Lauren, Smart, Brandon, Williams, Hannah, Maxwell, Dylan, Hunt, Jeremy, Yang, Wentao, Crews, Kristine R., Roberts, Kathryn G., Jeha, Sima, Cheng, Cheng, Karol, Seth E., Relling, Mary V., Rosner, Gary L., Inaba, Hiroto, Mullighan, Charles G., Pui, Ching-Hon, Evans, William E., Yang, Jun J.

“…Contemporary chemotherapy for childhood acute lymphoblastic leukemia (ALL) is risk-adapted based on clinical features, leukemia genomics and minimal residual…”
Get full text

Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study by Karol, Seth E, Alexander, Thomas B, Budhraja, Amit, Pounds, Stanley B, Canavera, Kristin, Wang, Lei, Wolf, Joshua, Klco, Jeffery M, Mead, Paul E, Das Gupta, Soumyasri, Kim, Su Y, Salem, Ahmed Hamed, Palenski, Tammy, Lacayo, Norman J, Pui, Ching-Hon, Opferman, Joseph T, Rubnitz, Jeffrey E

“…Outcomes for children with relapsed or refractory acute myeloid leukaemia remain poor. The BCL-2 inhibitor, venetoclax, has shown promising activity in…”
Get full text

Top advances of the year: Pediatric oncology by Pappo, Alberto S., Karol, Seth E., Bertrand, Kelsey C.

“…Accelerated discovery and collaborative research continue to highlight the remarkable progress that has been made in the diagnosis and treatment of pediatric…”
Get full text

Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge by Liu, Yiwei, Smith, Colton A, Panetta, John C, Yang, Wenjian, Thompson, Lauren E, Counts, Jacob P, Molinelli, Alejandro R, Pei, Deqing, Kornegay, Nancy M, Crews, Kristine R, Swanson, Hope, Cheng, Cheng, Karol, Seth E, Evans, William E, Inaba, Hiroto, Pui, Ching-Hon, Jeha, Sima, Relling, Mary V

“…Pegaspargase (PEG-ASP) has largely replaced native asparaginase (L-ASP) in the treatment of acute lymphoblastic leukemia because of its longer half-life and…”
Get full text

Dosing of Venetoclax in Pediatric Patients with Relapsed Acute Myeloid Leukemia: Analysis of Developmental Pharmacokinetics and Exposure-Response Relationships by Badawi, Mohamed, Gopalakrishnan, Sathej, Engelhardt, Benjamin, Palenski, Tammy, Karol, Seth E., Rubnitz, Jeffrey E., Menon, Rajeev, Salem, Ahmed Hamed

“…•Venetoclax plus chemotherapy is an approved therapy in adult R/R AML patients.•Venetoclax demonstrated robust efficacy in pediatric AML in early clinical…”
Get full text

Pharmacogenomics and ALL treatment: How to optimize therapy by Karol, Seth E., Yang, Jun J.

“…Inherited genetic variations may alter drug sensitivity in patients with acute lymphoblastic leukemia, predisposing to adverse treatment side effects. In this…”
Get full text

NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells by Paugh, Steven W, Bonten, Erik J, Savic, Daniel, Ramsey, Laura B, Thierfelder, William E, Gurung, Prajwal, Malireddi, R K Subbarao, Actis, Marcelo, Mayasundari, Anand, Min, Jaeki, Coss, David R, Laudermilk, Lucas T, Panetta, John C, McCorkle, J Robert, Fan, Yiping, Crews, Kristine R, Stocco, Gabriele, Wilkinson, Mark R, Ferreira, Antonio M, Cheng, Cheng, Yang, Wenjian, Karol, Seth E, Fernandez, Christian A, Diouf, Barthelemy, Smith, Colton, Hicks, J Kevin, Zanut, Alessandra, Giordanengo, Audrey, Crona, Daniel, Bianchi, Joy J, Holmfeldt, Linda, Mullighan, Charles G, den Boer, Monique L, Pieters, Rob, Jeha, Sima, Dunwell, Thomas L, Latif, Farida, Bhojwani, Deepa, Carroll, William L, Pui, Ching-Hon, Myers, Richard M, Guy, R Kiplin, Kanneganti, Thirumala-Devi, Relling, Mary V, Evans, William E

“…William Evans and colleagues find that the proinflammatory genes CASP1 and NLRP3 are expressed at higher levels in primary acute lymphoblastic leukemia cells…”
Get full text

Incidence of hip and knee osteonecrosis and their associations with bone mineral density in children with acute lymphoblastic leukaemia by Inaba, Hiroto, Cao, Xueyuan, Chang, Jennifer Y., Karol, Seth E., Panetta, John C., Ness, Kirsten K., Cheng, Cheng, Pui, Ching‐Hon, Relling, Mary V., Kaste, Sue C.

Get full text

Predicting success of desensitization after pegaspargase allergy by Swanson, Hope D., Panetta, John C., Barker, Patricia J., Liu, Yiwei, Inaba, Hiroto, Relling, Mary V., Pui, Ching-Hon, Karol, Seth E.

Get full text

Genomic analysis of venous thrombosis in children with acute lymphoblastic leukemia from diverse ancestries by Zheng, Yan, Yang, Wenjian, Estepp, Jeremie, Pei, Deqing, Cheng, Cheng, Takemoto, Clifford M, Inaba, Hiroto, Jeha, Sima, Pui, Ching-Hon, Relling, Mary V, Karol, Seth E

“…Venous thrombosis is a common adverse effect of modern therapy for acute lymphoblastic leukemia (ALL). Prior studies to identify risks of thrombosis in…”
Get full text

Asparaginase combined with discontinuous dexamethasone improves antileukemic efficacy without increasing osteonecrosis in preclinical models by Karol, Seth E, Janke, Laura J, Panetta, John C, Ramsey, Laura B, Cai, Xiangjun, Payton, Monique A, Jenkins, David A, Evans, William E, Relling, Mary V

“…Combination therapy for acute lymphoblastic leukemia (ALL) is highly effective but results in significant toxicity including osteonecrosis. Asparaginase is…”
Get full text

Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia by Yoshimura, Satoshi, Panetta, John C., Hu, Jianzhong, Li, Lie, Gocho, Yoshihiro, Du, Guoqing, Umezawa, Akihiro, Karol, Seth E., Pui, Ching-Hon, Mullighan, Charles G., Konopleva, Marina, Stock, Wendy, Teachey, David T., Jain, Nitin, Yang, Jun J.

“…LCK is a novel therapeutic target in ~40% of T-cell acute lymphoblastic leukemia (T-ALL), and dasatinib and ponatinib can act as LCK inhibitors with…”
Get full text

Prognostic and Pharmacotypic Heterogeneity of Hyperdiploidy in Childhood ALL by Lee, Shawn H R, Ashcraft, Emily, Yang, Wenjian, Roberts, Kathryn G, Gocho, Yoshihiro, Rowland, Lauren, Inaba, Hiroto, Karol, Seth E, Jeha, Sima, Crews, Kristine R, Mullighan, Charles G, Relling, Mary V, Evans, William E, Cheng, Cheng, Yang, Jun J, Pui, Ching-Hon

“…High hyperdiploidy, the largest and favorable subtype of childhood ALL, exhibits significant biological and prognostic heterogeneity. However, factors…”
Get full text

Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemia by Huang, Xin, Li, Yizhen, Zhang, Jingliao, Yan, Lei, Zhao, Huanbin, Ding, Liang, Bhatara, Sheetal, Yang, Xu, Yoshimura, Satoshi, Yang, Wenjian, Karol, Seth E, Inaba, Hiroto, Mullighan, Charles, Litzow, Mark, Zhu, Xiaofan, Zhang, Yingchi, Stock, Wendy, Jain, Nitin, Jabbour, Elias, Kornblau, Steven M, Konopleva, Marina, Pui, Ching-Hon, Paietta, Elisabeth, Evans, William, Yu, Jiyang, Yang, Jun J

“…Leukemia can arise at various stages of the hematopoietic differentiation hierarchy, but the impact of developmental arrest on drug sensitivity is unclear…”
Get more information

Fenofibrate reduces osteonecrosis without affecting antileukemic efficacy in dexamethasone treated mice by Finch, Emily R, Payton, Monique A, Jenkins, David A, Cai, Xiangjun, Li, Lie, Karol, Seth E, Relling, Mary V, Janke, Laura J

“…Recent clinical trials in children with acute lymphoblastic leukemia (ALL) indicate that severe hypertriglyceridemia (> 1000 mg/dL) during therapy is…”
Get full text

Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia by Karol, Seth E., Yang, Wenjian, Van Driest, Sara L., Chang, Tamara Y., Kaste, Sue, Bowton, Erica, Basford, Melissa, Bastarache, Lisa, Roden, Dan M., Denny, Joshua C., Larsen, Eric, Winick, Naomi, Carroll, William L., Cheng, Cheng, Pei, Deqing, Fernandez, Christian A., Liu, Chengcheng, Smith, Colton, Loh, Mignon L., Raetz, Elizabeth A., Hunger, Stephen P., Scheet, Paul, Jeha, Sima, Pui, Ching-Hon, Evans, William E., Devidas, Meenakshi, Mattano, Leonard A., Relling, Mary V.

“…Glucocorticoids are important therapy for acute lymphoblastic leukemia (ALL) and their major adverse effect is osteonecrosis. Our goal was to identify genetic…”
Get full text

Outcomes in patients with ETV6::RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies by Purvis, Katelyn, Zhou, Yinmei, Karol, Seth E, Rubnitz, Jeffrey E, Ribeiro, Raul C, Lee, Shawn Hr, Yang, Jun J, Bowman, W Paul, Wang, Lu, Dixon, Stephanie B, Roberts, Kathryn G, Gao, Qingsong, Cheng, Cheng, Mullighan, Charles G, Jeha, Sima, Pui, Ching-Hon, Inaba, Hiroto

“…Children with ETV6::RUNX1 or high-hyperdiploid B-acute lymphoblastic leukemia (B-ALL) have favorable outcomes. The St. Jude (SJ) classification considers these…”
Get full text

Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy by Jeha, Sima, Choi, John, Roberts, Kathryn G, Pei, Deqing, Coustan-Smith, Elaine, Inaba, Hiroto, Rubnitz, Jeffrey E, Ribeiro, Raul C, Gruber, Tanja A, Raimondi, Susana C, Karol, Seth E, Qu, Chunxu, Brady, Samuel W, Gu, Zhaohui, Yang, Jun J, Cheng, Cheng, Downing, James R, Evans, Williams E, Relling, Mary V, Campana, Dario, Mullighan, Charles G, Pui, Ching-Hon

“…We evaluate clinical significance of recently identified subtypes of acute lymphoblastic leukemia (ALL) in 598 children treated with minimal residual disease…”
Get full text

Rituximab administration in pediatric patients with newly diagnosed acute lymphoblastic leukemia by Hoshitsuki, Keito, Zhou, Yinmei, Miller, April M., Choi, John K., Swanson, Hope D., Bhakta, Nickhill H., Jeha, Sima, Karol, Seth E., Ribeiro, Raul C., Rubnitz, Jeffrey E., Mullighan, Charles G., Cheng, Cheng, Yang, Jun J., Relling, Mary V., Pui, Ching-Hon, Inaba, Hiroto

“…Polyethylene glycol (PEG)-asparaginase (pegaspargase) is a key agent in chemotherapy for acute lymphoblastic leukemia (ALL), but recipients frequently…”
Get full text